Eli Lilly (LLY) earnings Q2 2026
Eli Lilly on Wednesday reported second-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook,…
Insilico Medicine highlights AI-powered biological target discovery for rare sinonasal cancer
Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative…
Eli Lilly to offer retatrutide access given earlier to just one patient
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
ESCRT-III proteins play an unexpected role in protecting DNA bridges during cell division
Every time a cell divides, it must accurately copy and distribute its DNA between two new cells. However,…
7 life-saving medical innovations that could redefine healthcare
Over the past few years, several innovations have crossed important milestones, moving from experimental concepts toward real-world patient…
Advancements in Antibody Technologies for Better Health
IntroductionWhat Are Antibodies?Antibodies as Research and Diagnostic ToolsThe Rise of Therapeutic AntibodiesADCsBispecific Antibodies and T-Cell EngagersFuture DirectionsConclusionReferencesFurther Reading…
Eli Lilly will file for approval of retatrutide obesity drug in 2027
The Eli Lilly logo appears on the company’s office in San Diego, California, Nov. 21, 2025. Mike Blake…
Precise DNA base editing using AlphaFold3-based contact modelling
Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR-Cas nucleases, base editors, transposases…
SynGenSys makes key appointments to strengthen senior commercial and scientific teams
SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance…
AI-powered closed-loop wearable bioelectronics for personalized and autonomous healthcare
Chen, C., Ding, S. & Wang, J. Digital health for aging populations. Nat. Med. 29, 1623–1630 (2023). Article …
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…
Ozempic for cats? GLP-1 weight-loss drugs are coming for your fat pet
A beautiful, but over weight Maine Coon Cat gets measured around the belly by a vet. Ryersonclark |…